(Reuters) - The U.S. Department of Defense has exercised an option with Canada's Tekmira Pharmaceuticals Corp for the company to make 500 courses of its experimental treatment for Ebola, Tekmira said on Thursday.
The treatment targets the Ebola-Guinea virus variant, which is responsible for the worst outbreak on record that has hit hardest in Liberia, Sierra Leone and Guinea. It works by preventing the virus from replicating.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
